This project is based on our discovery that genetic mutations in molecules that control the programmed death, or apoptosis, of lymphocytes are responsible for the Autoimmune Lymphoproliferative Syndrome (ALPS). ALPS is a disease affecting children that leads to loss of normal lymphocyte homeostasis leading to swollen lymph glands and organs. Because lymphocytes are the primary cell mediating immune reactions, this excess of lymphocytes leads to a pathological autoimmune attack on the patients own tissues. We have identified mutations in a death-inducing cell surface receptor termed Fas (also known as APO-1 or CD95) and in other molecules that regulate apoptosis. We have also identified a new disease entity called, Caspase-8 Deficiency State (CEDS) that is due to a genetic deficiency of caspase-8. This disease involves a loss of apoptotic control and lymphocyte expansion combined with a failure of normal lymphocyte activation through the antigen receptors. The consequence of this is a profound immunodeficiency state and a new insight that caspase-8, heretofore regarded solely as a cell death inducing protease, has a key role in antigen receptor signaling particularly for the induction of a gene regulatory factor called NF-kB. These studies promise to provide new insights into the molecular mechanisms that underlie autoimmune and immunodeficiency disease as well as revealing crucial steps in the pathway of programmed cell death in lymphocytes. In other related studies, have developed a new rapid and reliable assay for assessing the Fas apoptosis defect in clinical specimens. We are presently studying a class of these patients called ALPS Type III which do not display mutations in the Fas receptor, its ligand (Fas ligand), or caspase-10. We are using a variety of molecular analyses to determine the gene mutation that underlies disease in ALPS Type III. These experiments have been successful in uncovering the molecular basis of a new class of this disease, ALPS type IV. Patients with this disorder have typical clinical features of autoimmunity and abnormal lymphocyte homeostasis that are detected in ALPS, type I and II. however, these patients differ in that they have a strikingly decreased death in response to cytokine withdrawal rather than a defect in death receptor apoptosis. The molecular basis of this disorder is a reduction in the apoptosis protein Bim due to an inherited germline mutation in the N-Ras oncogene. We plan to continue to examine unusual Alps Type III cases to understand their molecular basis. Our guiding principle is that patient specimens from poorly understood diseases can yield valuable insights into disease mechanisms and normal physiology if investigated properly at the molecular level. We have found several new mutations in these unusual patient disorders and are currently characterizing their role in lymphocyte homeostasis and apoptosis.

Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2013
Total Cost
$558,614
Indirect Cost
City
State
Country
Zip Code
Similuk, Morgan; Rao, V Koneti; Churpek, Jane et al. (2016) Predispositions to Lymphoma: A Practical Review for Genetic Counselors. J Genet Couns :
Lo, Bernice; Fritz, Jill M; Su, Helen C et al. (2016) CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood 128:1037-42
Lenardo, Michael; Lo, Bernice; Lucas, Carrie L (2016) Genomics of Immune Diseases and New Therapies. Annu Rev Immunol 34:121-49
Similuk, Morgan N; Wang, Angela; Lenardo, Michael J et al. (2016) Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda. J Clin Immunol 36:123-33
Calvo, Katherine R; Price, Susan; Braylan, Raul C et al. (2015) JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood 125:2753-8
Lo, Bernice; Zhang, Kejian; Lu, Wei et al. (2015) AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349:436-40
Lucas, Carrie L; Lenardo, Michael J (2015) Identifying genetic determinants of autoimmunity and immune dysregulation. Curr Opin Immunol 37:28-33
Zhang, Yu; Su, Helen C; Lenardo, Michael J (2015) Genomics is rapidly advancing precision medicine for immunological disorders. Nat Immunol 16:1001-4
Price, Susan; Shaw, Pamela A; Seitz, Amy et al. (2014) Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123:1989-99
Kuehn, Hye Sun; Ouyang, Weiming; Lo, Bernice et al. (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345:1623-7

Showing the most recent 10 out of 28 publications